Free-text search
Articles per year:
Content Types
-
Orbán's extended arm becomes health commissioner in the EU
Hungarian Olivér Várhelyi may soon become the most influential official for the healthcare and pharmaceutical industry in the EU. Várhelyi, who is close to Hungarian prime minister Viktor Orbán, is seen as a controversial figure due to his opposition to abortion and for calling EU members ”idiots.”
-
Drug development booms in Medicon Valley
When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical companies are highlighted as a success factor. “Everyone has heard of Novo Nordisk
-
The key to successful collaboration between industry and academia
Why is collaboration between industry and academia necessary in the life sciences sector? What obstacles exist, and what is the key to successful collaboration?
-
Lilly´s Nordic manager on Mounjaro launch in Sweden: "Patients deserve respect"
Another blockbuster diabetes and obesity drug has made its way into the Swedish market – with promises of a stable supply and availability for patients. “What we see is a significant unmet need, so we are expecting to have quite a good welcoming in the market", says Daniel Lucas, Managing Director Nordic Countries at the American pharmaceutical giant Eli Lilly.
-
”The importance of stratification in a statistician’s August kitchen”
Ingrid Lönnstedt writes about an experiment of her own at home and about what lessons can be learned from it, in a science column.
-
A new life science cluster formed – “We are very strong in talent”
Stockholm and Uppsala’s joint life science cluster aims to be among the best in Europe. Pontus Holm, Life Science Coordinator for Region Stockholm, says the decision to create a joint profile for the two cities is strongly supported. He mentions that around 50 stakeholders were asked last winter if they were in favour of a joint cluster and that “the answer was a resounding yes”.
-
Forflytning med omtanke
Det danskproducerede loftliftsystem med den velkendte ellipseformede loftlift kommer til januar 2025 i en helt ny version. Skinnesystemet er fremstillet af genanvendt aluminium, der reducerer CO₂ aftrykket med 66 % på Scope 3 niveau. Liften vejer desuden kun 5.2 kg og dermed en yderligere reduktion af CO₂ aftrykket. Den innovative lift fra Winncare gør det lettere for sundhedssektoren at foretage et mere miljøbevidst valg.
-
Her company is developing a new tablet form obesity drug
Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the billion-selling GLP1 analogues. ‘‘Basically, I expect all the beneficial effects that they have, but not the same side effect profile,’’ company founder Dorte X Gram said in an interview with Life Science Sweden.
-
Stockholm and Uppsala jointly form a life science cluster
Stockholm and Uppsala are strengthening cooperation in medical research and biotech.
-
Forflytning med omtanke
Det danskproducerede loftliftsystem med den velkendte ellipseformede loftlift kommer til januar 2025 i en helt ny version. Skinnesystemet er fremstillet af genanvendt aluminium, der reducerer CO₂ aftrykket med 66 % på Scope 3 niveau. Liften vejer desuden kun 5.2 kg og dermed en yderligere reduktion af CO₂ aftrykket. Den innovative lift fra Winncare gør det lettere for sundhedssektoren at foretage et mere miljøbevidst valg.
-
Sectra får kanadensisk miljardorder
Det Linköpingsbaserade medtechbolaget Sectra ska förse alla offentliga sjukhus i provinsen Québec i Kanada med sin helhetslösning för medicinsk bildhantering. Ordervärdet är 405,5 miljoner kanadensiska dollar, motsvarande drygt 3 miljarder kronor.
-
An increasing number of people are falling ill with TBE – “Much more research is needed”
Tick-borne meningitis, or TBE, is an increasingly common disease in Sweden. Currently, there is a vaccine against the disease but no drugs. Researcher Anna Överby Wernstedt is studying the processes that occur in the brain during a TBE infection and hopes to contribute to developing a treatment.
-
From lab to patient – the art of developing new antibody therapies
For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along for much of the journey and has experienced setbacks, but also huge discoveries. “It’s amazing when you succeed,” she says.
-
“We should avoid surgery if we can”
Since February this year, she has been Scientific Director Life Science at the Karolinska Institutet. Life Science Sweden met Anna Martling for a talk about role models, surgery and Sweden’s strengths and weaknesses in medical research.
-
What will be the next big hype after obesity? – An expert panel highlighted their top picks
What will be the next big trend in life science? Everything from Alzheimer’s, Crispr and Omics were highlighted when the issue was debated at this year’s major life science event in Lund.
-
Ingrid Lönnstedt: ”The confidence interval and its width”
Always keep an eye on the width of your and others’ confidence intervals, writes Ingrid Lönnstedt in a science column.
-
MSD discontinues two Keytruda trials
MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.
-
Ambu var ved at drukne: Britt Meelby Jensen blev redningskvinden
MedTechNews tegner et portræt af den street smarte direktør, der genrejser en af branchens kæmper
-
Efter profileret frasalg til rival vil GN-direktør ikke sælge yderligere
Gælden skulle skæres ned. Selskabet skulle trimmes. Nu, lyder det fra den adm. direktør, er GN Store Nord i balance
-
Anna Törner: Yes, I Am Sick, But Not Weak
”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be respected, to not have their identity overshadowed by their condition”, writes Anna Törner
-
DI om skelsættende sundhedsreform: Vi har brug for ét samlet sundhedsvæsen
Den vigtigste sundhedspolitiske beslutning i en generation skal træffes om kort tid. Dansk Industri vil samle ansvar og budgetter i ét sundhedsvæsen
-
Thumbs down for lecanemab in the EU – “Very surprised”
The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), according to an announcement made by the Agency last week. Bioarctic’s CEO Gunilla Osswald describes the reactions after the announcement as a surprise and disappointment.
-
Her er fem af branchens profiler: Tilsammen tjener de 100 millioner kroner om året
Topledere i landets børsnoterede selskaber får mere end 20 millioner kroner i løn om året. En headhunter opstiller profilen
-
Gothenburg, the city of life science – We are ‘Little Boston’
Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other industries for inspiration and knowledge.
BREAKING